Inflammatory Bowel Diseases  >>  Ozespa (briakinumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ozespa (briakinumab) / AbbVie
NCT00007163: Monoclonal Antibody Treatment of Crohn's Disease

Completed
1
40
US
J695
National Institute of Allergy and Infectious Diseases (NIAID)
Crohn's Disease
 
11/02

Download Options